Puma Biotechnology, Inc. (PBYI)
Automate Your Wheel Strategy on PBYI
With Tiblio's Option Bot, you can configure your own wheel strategy including PBYI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PBYI
- Rev/Share 4.6921
- Book/Share 1.958
- PB 1.8642
- Debt/Equity 0.5259
- CurrentRatio 1.529
- ROIC 0.2805
- MktCap 181179065.0
- FreeCF/Share 0.6284
- PFCF 5.8132
- PE 4.7554
- Debt/Assets 0.2603
- DivYield 0
- ROE 0.493
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Read More
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Read More
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss of 5 cents per share.
Read More
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Heather Blaber - VP of Marketing Roger Storms - VP of Sales Maximo Nougues - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Operator Good afternoon. My name is Sherry, and I will be your conference call operator today.
Read More
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Puma Biotech (PBYI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis.
Read More
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – President and Chief Executive Officer Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Marc Frahm – TD Cowen Operator Good afternoon.
Read More
About Puma Biotechnology, Inc. (PBYI)
- IPO Date 2012-04-24
- Website https://www.pumabiotechnology.com
- Industry Biotechnology
- CEO Mr. Alan H. Auerbach
- Employees 172